8 results about "HIV Antigens" patented technology

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins of the MPER region of gp140 as well as having a CD4 domain that binds to the CD4bs of gp120.

This application discloses an HIV antigen comprising the gp41 protein; said gp41 protein contains at least one amino acid residue selected from the following: T at position 85; K at position 98; a basic amino acid R or K at position 109; a neutral amino acid L or I at position 111; a basic amino acid K or R at position 132; N at position 133; and an acidic amino acid D or E at position 139. The HIV antigen of this application has the advantages of high specificity and high sensitivity.

The invention relates to the field of bioengineering, and discloses a human immunodeficiency virus p24 antigen and antibody detection kit and a preparation method thereof. The kit comprises a colloidal gold marker composite pad, wherein the colloidal gold marker composite pad comprises a p24 antibody colloidal gold marker, an HIV antigen colloidal gold marker and a chicken IgY antibody colloidal gold marker; an AG line, an AB line and a C line are arranged on the NC membrane, the AG line is coated with a p24 monoclonal antibody, the AB line is coated with HIV-I, HIV-II and HIV-O mixed antigens, and the C line is coated with goat anti-chicken IgY; and a sample pad, a conjugate pad and a water absorbent pad. The human immunodeficiency virus p24 antigen and antibody detection kit provided by the invention is obviously superior to the prior art in the aspects of sensitivity, specificity, convenience and stability, and has important clinical application and market values.

To provide a therapeutic or prophylactic vaccine for HIV disease.SOLUTION: A composition for delivering an antigen-expression system is provided, wherein the antigen-expression system comprises a vector backbone comprising a chimpanzee adenovirus vector, which is optionally a ChAdV68 vector, or an alphavirus vector, which is optionally a Venezuelan equine encephalitis virus vector, wherein the vector backbone comprises at least one HIV MHC class I antigen-encoding nucleotide sequence comprising an MHC class I epitope-encoding nucleotide sequence, wherein optionally the MHC class I epitope-encoding nucleotide sequence encodes an MHC class I epitope comprising at least one HIV epitope selected from the group consisting of the specified sequences.SELECTED DRAWING: Figure 34

This invention relates to the field of immunodiagnostics and provides recombinant HIV antigens for HIV antibody detection. Specifically, it concerns recombinant HIV antigens, nucleic acid molecules, expression vectors, host cells, reagents, kits, and their use. When recombinant HIV antigen proteins are used as the labeling end, the marker activity of the recombinant HIV antigen can be significantly improved, and nonspecific immunobinding activity can be reduced, thereby increasing sensitivity.

To provide a multispecific antigen-binding molecule targeting HIV and a method for its use. [Solution] A multispecific antigen-binding molecule is provided, comprising a bispecific antibody that binds to CD3 containing the HIV envelope protein gp120 and to the HIV antigen. Methods of using such an antigen-binding molecule to treat or prevent HIV infection are also provided. In some embodiments, the multispecific or bispecific molecule comprises a first antigen-binding domain targeting human CD3, which is a single-chain variable fragment (scFv) fused to Fc, while a second antigen-binding domain targeting the HIV antigen (e.g., gp120 or gp41) consists of a Fab antigen-binding fragment fused to Fc.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins of the V1 / V2 apex region of glycoprotein 120 (gp120) or the gp120-gp41 interface region of gp120 and gp41 as well as having a CD4 domain that binds to the CD4bs of gp120.